Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria

NCT04175704 is registered in ClinicalTrials.gov with United BioPharma as lead sponsor.

NCT NCT04175704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04175704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Lead sponsor
United BioPharma
Phase
Phase 1
Overall status
Unknown status
Start date
December 30, 2023
Completion date
January 30, 2026
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic urticaria